Research programme: non-fusion inhibitors - Vaxart/Georgia State University
Latest Information Update: 28 Aug 2020
At a glance
- Originator Aviragen Therapeutics; Georgia State University
- Developer Georgia State University; Vaxart
- Class Antivirals
- Mechanism of Action Viral RNA inhibitors; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Respiratory syncytial virus infections
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Respiratory-syncytial-virus-infections in USA
- 13 Feb 2018 Aviragen Therapeutics has merged with Vaxart forming Vaxart